The Truth About GLP-1 Weight Loss Drugs: Muscle Loss Microdosing & Long-Term Use

Two Doctors, Three Big Questions About GLP-1 Drugs

This conversation between Dr. Anthony Youn (a plastic surgeon known for his large YouTube following) and Dr. Spencer Nadolsky (a board-certified obesity medicine physician) zeroes in on three questions that come up constantly in GLP-1 discussions: How bad is the muscle loss? Does microdosing work? And how long should you actually stay on these drugs?

It is a focused conversation, which makes it more useful than many of the sprawling Ozempic videos that try to cover everything.

Muscle Loss: How Bad Is It Really?

The muscle loss conversation has become one of the defining concerns around GLP-1 medications. Nadolsky brings data to the table. In the STEP trials for semaglutide, roughly 30-40% of total weight lost was lean mass. That sounds alarming, and in some contexts it is.

But Nadolsky adds nuance that is often missing from the headlines. When anyone loses a lot of weight, regardless of the method, some lean mass loss is expected. Even with caloric restriction and exercise alone, you lose some muscle. The question is whether GLP-1 drugs cause proportionally more lean mass loss than other methods of weight loss.

The answer is: probably somewhat, but the gap narrows significantly when patients do resistance training and eat adequate protein. Nadolsky cites evidence showing that high protein intake (1 gram per pound of ideal body weight) combined with strength training can preserve most of the lean mass that would otherwise be lost.

Youn raises the cosmetic angle. Patients come to him after major weight loss on GLP-1 drugs with loose skin and a deflated appearance. From a plastic surgery standpoint, preserving muscle matters for metabolic health and for how you look and feel in your body after the weight is gone.

The Microdosing Trend

Microdosing GLP-1 drugs has picked up traction online. The idea is simple: take a lower dose than prescribed, either to reduce side effects, make the drug last longer (and cost less), or maintain weight loss that was achieved at a higher dose.

Nadolsky's take is measured. He has seen patients who respond well to lower doses. Some people are highly sensitive to semaglutide and get good appetite suppression at 0.25mg or 0.5mg, doses that are technically part of the titration phase rather than the maintenance dose. For those people, staying at a lower dose might make sense.

But he warns against unstructured microdosing without medical supervision. The dose-response relationship is real. Below a certain threshold, the drug does not do much. And the trend of splitting pens or using compounded semaglutide at improvised doses introduces quality control and dosing accuracy concerns.

He also points out that microdosing has not been studied in clinical trials. The efficacy and safety data we have is for the standard dosing schedule. Anything outside of that is essentially uncharted territory, even if the anecdotal reports sound promising.

Long-Term Use: Stay On or Taper Off?

This might be the biggest unanswered question in GLP-1 medicine right now. The drugs work while you take them. Most people regain weight when they stop. So are you supposed to take them forever?

Nadolsky breaks this into categories. For patients with severe obesity and multiple comorbidities, long-term use may be appropriate, just like you would take blood pressure medication indefinitely. Obesity is a chronic disease, and treating it with chronic medication is not inherently different from treating hypertension or diabetes.

For patients who used GLP-1 drugs to lose a moderate amount of weight and who have successfully adopted new eating and exercise habits, a supervised taper might work. Nadolsky says he has patients who stepped down gradually and maintained their weight loss. But he is honest that this is the minority. More patients regain than maintain after stopping.

The conversation also touches on intermittent use. Could you take semaglutide for a year, stop for a year, and restart if weight creeps up? Nadolsky says there is no data to support or refute this approach, but it is something he has discussed with patients who want to avoid indefinite use.

The Insurance and Access Problem

Both doctors acknowledge that the discussion about dosing strategy and long-term use is somewhat academic for many patients. Insurance coverage for GLP-1 drugs remains inconsistent. Some plans cover them for diabetes but not for weight loss. Others deny coverage entirely. This forces patients to make decisions based on cost rather than optimal medical strategy.

Microdosing, in some cases, is driven by economics rather than clinical reasoning. A patient who cannot afford $1,200 per month for semaglutide might stretch a single pen across two months at half the intended dose. Nadolsky understands the reality of this but stresses that dose modifications should still involve a prescriber who can monitor outcomes and adjust the plan.

The Actual Muscle Preservation Protocol That Works

Nadolsky says high protein and resistance training are non-negotiable, but the video does not get specific enough for someone to build a plan from. Here is what the evidence and clinical practice support.

Protein target: 1 gram per pound of ideal body weight per day, spread across 3-4 meals. For a person whose ideal weight is 160 pounds, that means 40 grams of protein per meal, four times a day. On a reduced-calorie GLP-1 diet, this means protein takes up the majority of your calories. A typical day might look like: eggs and Greek yogurt at breakfast, a chicken breast salad at lunch, a protein shake in the afternoon, and fish or lean beef with vegetables at dinner.

Resistance training: 3-4 sessions per week focusing on compound movements. Squats, deadlifts, bench press, overhead press, rows, and pull-ups (or assisted pull-ups). These exercises recruit the most muscle mass per movement, which gives you the best return on your training time. If you are new to lifting, working with a trainer for the first month to learn proper form is a worthwhile investment.

Creatine monohydrate: 3-5 grams daily. This is one of the most studied supplements in sports science, with decades of safety data. It supports muscle retention during caloric deficit and can improve training performance. No loading phase needed. Just take it consistently.

Sleep: 7-9 hours per night. Growth hormone is released primarily during deep sleep, and growth hormone is a key driver of muscle protein synthesis. Chronic sleep deprivation undermines muscle preservation regardless of how well you eat and train.

The Real Cost of Microdosing vs. Standard Dosing

The microdosing trend is partly driven by clinical preference and partly by economics, and it helps to separate the two motivations. Clinically, some patients are genuinely sensitive to semaglutide and get adequate results at 0.25mg or 0.5mg per week. For them, staying at a lower dose means fewer side effects with sufficient appetite suppression. That is a sound medical decision made with their prescriber.

Economically, patients who cannot afford $1,000+ per month for brand-name semaglutide stretch a single pen across multiple weeks. A Wegovy pen at the 2.4mg dose contains four weekly doses. If someone takes 0.6mg per week instead of 2.4mg, that single pen lasts 16 weeks instead of 4. At cash prices, that drops the monthly cost from roughly $1,300 to around $325.

The problem is that economic microdosing skips the clinical question: is 0.6mg enough for you? Some people will see real results. Others will get minimal benefit and conclude the drug does not work, when the real issue was inadequate dosing. If cost is the driver, compounded semaglutide at $200-400 per month may be a better option than underdosing the brand-name product, assuming you use a reputable pharmacy (see the FormBlends write-up on "Can You Trust Ozempic or Mounjaro From a Compounding Pharmacy?" for how to vet one).

A Decision Framework for Long-Term Use vs. Tapering

Since the video leaves the long-term use question somewhat open, here is a framework to discuss with your prescriber based on what obesity medicine physicians are doing in practice.

Stay on long-term if: your BMI was 40+ before treatment, you have weight-responsive comorbidities (sleep apnea, type 2 diabetes, hypertension) that resolved on the medication, or you have a history of repeated weight loss and regain cycles. The rationale is the same as long-term blood pressure medication. The condition is chronic, and stopping treatment means the condition returns.

Consider a supervised taper if: you have reached your goal weight, your BMI is now under 30, you have established consistent exercise and eating habits that feel sustainable without pharmaceutical appetite suppression, and you have a plan for monitoring and restarting if weight regain exceeds a defined threshold (typically 5-10% above your lowest weight).

Try intermittent use if: you want to avoid indefinite medication but recognize you may need periodic support. Some prescribers are experimenting with "courses" of GLP-1 therapy: 6-12 months on, then off, with a clear re-start trigger if weight climbs above a threshold. No clinical trial has validated this approach, but it represents a pragmatic middle ground between lifelong medication and cold-turkey discontinuation.

What the Video Does Not Address

This conversation stays focused on its three questions, which is a strength. But there are related topics it does not cover that matter for anyone weighing these decisions. It does not discuss the newer oral semaglutide formulations that are in late-stage trials, which could change the cost and convenience equation significantly. It does not touch on the emerging data around retatrutide and other next-generation GLP-1 combinations that may produce better lean mass preservation. And while Nadolsky mentions tapering, the specific protocols for how to taper (how fast, to what minimum dose, with what monitoring) are left vague. If you are considering a taper, that is a conversation for your prescriber, not something to improvise based on a YouTube video.

Where Both Doctors Agree

Despite coming from different specialties, Youn and Nadolsky agree on several points. First, GLP-1 drugs are legitimate medications with real benefits for the right patients. Second, the hype cycle has outpaced the evidence in some areas, especially around microdosing and long-term safety. Third, anyone on these drugs should be doing resistance training and eating high protein. That is not optional advice. It is the minimum standard of care for preserving your health while losing weight on GLP-1 medication.

The format works well here. Two doctors with different patient populations, talking through the same questions from different angles. If you are trying to figure out your own approach to GLP-1 drugs, this is a solid 30 minutes of straightforward medical thinking.